Improved Survival in Lung Cancer with Combined Therapy
Author Information
Author(s): Schad Friedemann, Thronicke Anja, Hofheinz Ralf-Dieter, Klein Reinhild, Grabowski Patricia, Oei Shiao Li, Wüstefeld Hannah, Grah Christian
Primary Institution: Network Oncology Registry, Research Institute Havelhöhe, Berlin, Germany
Hypothesis
Does the combination of immune checkpoint blockade and abnobaViscum® therapy improve survival in advanced or metastatic non-small-cell lung cancer patients?
Conclusion
The addition of abnobaViscum® to immune checkpoint blockade significantly improves survival in patients with advanced or metastatic non-small-cell lung cancer.
Supporting Evidence
- Overall survival was significantly prolonged in the COMB group by 7 months compared to CTRL.
- The survival rate was 16.5% in the COMB group vs. 8.0% in the CTRL group.
- In PD-L1 positive patients, the addition of abnobaViscum® reduced the adjusted hazard of death by 75%.
- The study adhered to ESMO-GROW criteria with ethics approval.
Takeaway
This study found that patients with lung cancer lived longer when they received a special mistletoe therapy along with their regular cancer treatment.
Methodology
Patients with advanced or metastatic NSCLC were analyzed using real-world data from a registry, comparing survival outcomes between those receiving immune checkpoint blockade alone and those receiving it with abnobaViscum® therapy.
Potential Biases
Potential for selection bias due to non-randomized patient assignment.
Limitations
The non-randomized nature of the study may introduce selection bias.
Participant Demographics
Median age of participants was 68 years, with a male/female ratio of 1.19.
Statistical Information
P-Value
0.005
Confidence Interval
95%CI: 9.2–22 months
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website